Format

Send to

Choose Destination
Pediatr Clin North Am. 2015 Feb;62(1):225-56. doi: 10.1016/j.pcl.2014.09.015.

Neuroblastoma: paradigm for precision medicine.

Author information

1
Division of Hematology-Oncology, Hospital for Sick Children, University of Toronto, 555 University Ave, Toronto, ON M5G1X8, Canada.
2
Division of Hematology-Oncology, Seattle Children's Hospital, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, 4800 Sandpoint Way NE, Seattle, WA 98105, USA. Electronic address: julie.park@seattlechildrens.org.

Abstract

Neuroblastoma (NB) is the third most common pediatric cancer. Although NB accounts for 7% of pediatric malignancies, it is responsible for more than 10% of childhood cancer-related mortality. Prognosis and treatment are determined by clinical and biological risk factors. Estimated 5-year survival rates for patients with non-high-risk and high-risk NB are more than 90% and less than 50%, respectively. Recent clinical trials have continued to reduce therapy for patients with non-high-risk NB, including the most favorable subsets who are often followed with observation approaches. In contrast, high-risk patients are treated aggressively with chemotherapy, radiation, surgery, and myeloablative and immunotherapies.

KEYWORDS:

ALK (anaplastic lymphoma kinase); Immunotherapy; MYCN; Myeloablative therapy (MAT); Neuroblastoma; Phox2B; Risk stratification; Segmental chromosome aberrations (SCA)

PMID:
25435121
DOI:
10.1016/j.pcl.2014.09.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center